Author

Michael O’Dwyer

Haematology - Cited by 9,576 - Myeloma - Leukemia - glycosylation - oregon - galway

Biography

Dr. Michael O’Dwyer is a experienced Clinician Scientist with a strong track record in clinical and translational research in blood cancers. A graduate of the National University of Ireland, Galway. He undertook training in Internal Medicine and Hematology in Ireland, before moving to Portland, Oregon, where he was a Fellow and then Assistant Professor in the Department of Hematology and Medical Oncology at Oregon Health & Sciences University. While there he worked on the initial development of imatinib with Brian Druker and made important original observations on the role of clonal evolution in CML
Title
Cited by
Year
Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma (MAIA): overall survival results from a randomised …
T Facon, SK Kumar, T Plesner, RZ Orlowski, P Moreau, N Bahlis, S Basu, ...The Lancet Oncology 22 (11), 1582-1596, 2021202
110
2021
CD38 knockout natural killer cells expressing an affinity optimized CD38 chimeric antigen receptor successfully target acute myeloid leukemia with reduced effector cell fratricide
M Gurney, A Stikvoort, E Nolan, L Kirkham-McCarthy, S Khoruzhenko, ...Haematologica 107 (2), 437, 2022202
55
2022
Long-term (180-day) outcomes in critically ill patients with COVID-19 in the REMAP-CAP randomized clinical trial
S Florescu, D Stanciu, M Zaharia, A Kosa, D Codreanu, A Kidwai, ...Jama 3 (1), 39-51, 2023202
29
2023
Phase 1/2 study of uproleselan added to chemotherapy in patients with relapsed or refractory acute myeloid leukemia
DJ DeAngelo, BA Jonas, JL Liesveld, DL Bixby, AS Advani, P Marlton, ...Blood, The Journal of the American Society of Hematology 139 (8), 1135-1146, 2022202
29
2022
miR-130b and miR-128a are essential lineage-specific codrivers of t (4; 11) MLL-AF4 acute leukemia
C Malouf, ETB Antunes, M O’Dwyer, H Jakobczyk, F Sahm, SL Landua, ...Blood, The Journal of the American Society of Hematology 138 (21), 2066-2092, 2021202
19
2021
Targeting hypersialylation in multiple myeloma represents a novel approach to enhance NK cell–mediated tumor responses
J Daly, S Sarkar, A Natoni, JC Stark, NM Riley, CR Bertozzi, M Carlsten, ...Blood Advances 6 (11), 3352-3366, 2022202
18
2022
Addition of elotuzumab to lenalidomide and dexamethasone for patients with newly diagnosed, transplantation ineligible multiple myeloma (ELOQUENT-1): An open-label, multicentre …
MA Dimopoulos, PG Richardson, NJ Bahlis, S Grosicki, M Cavo, ...The Lancet Haematology 9 (6), e403-e414, 2022202
16
2022
Daratumumab plus lenalidomide and dexamethasone (D-Rd) versus lenalidomide and dexamethasone (Rd) alone in transplant-ineligible patients with newly diagnosed multiple myeloma …
SK Kumar, P Moreau, NJ Bahlis, T Facon, T Plesner, RZ Orlowski, S Basu, ...Blood 0 (Supplement 1), 10150-10153, 2022202
14
2022
Feeder cells at the interface of natural killer cell activation, expansion and gene editing
M Gurney, S Kundu, S Pandey, M O’DwyerFrontiers in Immunology 13, 802906, 2022202
11
2022
Daratumumab plus lenalidomide and dexamethasone (D-Rd) versus lenalidomide and dexamethasone (Rd) in transplant-ineligible patients (Pts) with newly diagnosed multiple myeloma …
P Moreau, T Facon, S Usmani, NJ Bahlis, N Raje, T Plesner, RZ Orlowski, ...Blood 140 (Supplement 1), 29-300, 2022202
7
2022
Daratumumab Plus Lenalidomide and Dexamethasone in Patients with Transplant-ineligible Newly Diagnosed Multiple Myeloma: MAIA Age Subgroup Analysis
T Facon, SK Kumar, K Weisel, S Usmani, P Moreau, T Plesner, ...Blood 140 (Supplement 1), 10133-10136, 2022202
7
2022
Efficacy of daratumumab, lenalidomide, and dexamethasone in transplant-ineligible patients with newly diagnosed multiple myeloma and impaired renal function from the phase 3 …
SZ Usmani, S Kumar, T Plesner, RZ Orlowski, P Moreau, NJ Bahlis, ...Blood 138, 1646, 2021202
5
2021
Effect of angiotensin-converting enzyme inhibitor and angiotensin receptor blocker initiation on organ support–free days in patients hospitalized with COVID-19: a randomized …
S Florescu, D Stanciu, M Zaharia, A Kosa, D Codreanu, K Fareed, ...JAMA 329 (1), 1183-1196, 2023202
4
2023
Effect of Antiplatelet Therapy on Survival and Organ Support–Free Days in Critically Ill Patients With COVID-19: A Randomized Clinical Trial
S Florescu, D Stanciu, M Zaharia, A Kosa, D Codreanu, A Kidwai, ...JAMA 37 (13), 147-159, 0
2
2022
Promising Preliminary Activity of Optimized Affinity, CD38 CAR NK Cells Generated Using a Non-Viral Engineering Approach in Gene Edited Cord Blood Derived NK Cells for the …
R Duggal, SS Santara, M Gordon, A Kilgallon, D Hermanson, RW Childs, ...Blood 38, 4793, 20220
1
2021
Targeting stromal cell sialylation reverses T cell-mediated immunosuppression in the tumor microenvironment
H Egan, O Treacy, K Lynch, NA Leonard, G O’Malley, E Reidy, A O’Neill, ...Cell Reports 42 (5), 2023202
1
2023
941 Stromal cell sialylation suppresses T cells in inflammatory tumour microenvironments: a new tumour stromal cell immune checkpoint?
94 Stromal cell sialylation suppresses T cells in inflammatory tumour microenvironments: a new tumour stromal cell immune checkpoint?O Treacy, H Egan, K Lynch, N Leonard, K De Veirman, K Vanderkerken, ...Journal for ImmunoTherapy of Cancer 9 (Suppl 2), 20220
1
2021
CyBorD-DARA in Newly Diagnosed Transplant-Eligible Multiple Myeloma: Results from the 16-BCNI-001/CTRIAL-IE 16-02 Study Show High Rates of MRD Negativity at End of Treatment
CyBorD-DARA in Newly Diagnosed Transplant-Eligible Multiple Myeloma: Results from the 6-BCNI-00/CTRIAL-IE 6-02 Study Show High Rates of MRD Negativity at End of TreatmentD Swan, R Henderson, C McEllistrim, SD Naicker, J Quinn, MR Cahill, ...Clinical Lymphoma Myeloma and Leukemia 22 (), 847-852, 2022202
1
2022
The EHA research roadmap: immune-based therapies for hematological malignancies
H Einsele, J Briones, F Ciceri, IG Cadenas, F Falkenburg, N Bolaños, ...HemaSphere 5 (0), 20220
1
2021

Referred From: https://scholar.google.com/citations?user=kogt9QsAAAAJ&hl=en

Cited by
Citations 9576
h-index 47
i10-index 113
Recommended Journals
Open Access Journals